Nanog signaling in cancer promotes stem-like phenotype and immune evasion

Kyung Hee Noh, Bo Wook Kim, Kwon Ho Song, Hanbyoul Cho, Young Ho Lee, Jin Hee Kim, Joon Yong Chung, Jae Hoon Kim, Stephen M. Hewitt, Seung Yong Seong, Chih Ping Mao, T. C. Wu, Tae Woo Kim

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Adaptation of tumor cells to the host is a major cause of cancer progression, failure of therapy, and ultimately death. Immune selection drives this adaptation in human cancer by enriching tumor cells with a cancer stem cell-like (CSC-like) phenotype that makes them resistant to CTL-mediated apoptosis; however, the mechanisms that mediate CSC maintenance and proliferation are largely unknown. Here, we report that CTL-mediated immune selection drives the evolution of tumor cells toward a CSC-like phenotype and that the CSC-like phenotype arises through the Akt signaling pathway via transcriptional induction of Tcl1a by Nanog. Furthermore, we found that hyperactivation of the Nanog/Tcl1a/Akt signaling axis was conserved across multiple types of human cancer. Inhibition of Nanog in a murine model of colon cancer rendered tumor cells susceptible to immune-mediated clearance and led to successful, long-term control of the disease. Our findings establish a firm link among immune selection, disease progression, and the development of a stem-like tumor phenotype in human cancer and implicate the Nanog/Tcl1a/Akt pathway as a central molecular target in this process.

Original languageEnglish
Pages (from-to)4077-4093
Number of pages17
JournalJournal of Clinical Investigation
Volume122
Issue number11
DOIs
Publication statusPublished - 2012 Nov 1

Fingerprint

Immune Evasion
Phenotype
Neoplasms
Neoplastic Stem Cells
Immune System Diseases
Colonic Neoplasms
Disease Progression
Maintenance
Apoptosis

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Noh, K. H., Kim, B. W., Song, K. H., Cho, H., Lee, Y. H., Kim, J. H., ... Kim, T. W. (2012). Nanog signaling in cancer promotes stem-like phenotype and immune evasion. Journal of Clinical Investigation, 122(11), 4077-4093. https://doi.org/10.1172/JCI64057
Noh, Kyung Hee ; Kim, Bo Wook ; Song, Kwon Ho ; Cho, Hanbyoul ; Lee, Young Ho ; Kim, Jin Hee ; Chung, Joon Yong ; Kim, Jae Hoon ; Hewitt, Stephen M. ; Seong, Seung Yong ; Mao, Chih Ping ; Wu, T. C. ; Kim, Tae Woo. / Nanog signaling in cancer promotes stem-like phenotype and immune evasion. In: Journal of Clinical Investigation. 2012 ; Vol. 122, No. 11. pp. 4077-4093.
@article{3e1ec0df24b540378ca79c57c3753574,
title = "Nanog signaling in cancer promotes stem-like phenotype and immune evasion",
abstract = "Adaptation of tumor cells to the host is a major cause of cancer progression, failure of therapy, and ultimately death. Immune selection drives this adaptation in human cancer by enriching tumor cells with a cancer stem cell-like (CSC-like) phenotype that makes them resistant to CTL-mediated apoptosis; however, the mechanisms that mediate CSC maintenance and proliferation are largely unknown. Here, we report that CTL-mediated immune selection drives the evolution of tumor cells toward a CSC-like phenotype and that the CSC-like phenotype arises through the Akt signaling pathway via transcriptional induction of Tcl1a by Nanog. Furthermore, we found that hyperactivation of the Nanog/Tcl1a/Akt signaling axis was conserved across multiple types of human cancer. Inhibition of Nanog in a murine model of colon cancer rendered tumor cells susceptible to immune-mediated clearance and led to successful, long-term control of the disease. Our findings establish a firm link among immune selection, disease progression, and the development of a stem-like tumor phenotype in human cancer and implicate the Nanog/Tcl1a/Akt pathway as a central molecular target in this process.",
author = "Noh, {Kyung Hee} and Kim, {Bo Wook} and Song, {Kwon Ho} and Hanbyoul Cho and Lee, {Young Ho} and Kim, {Jin Hee} and Chung, {Joon Yong} and Kim, {Jae Hoon} and Hewitt, {Stephen M.} and Seong, {Seung Yong} and Mao, {Chih Ping} and Wu, {T. C.} and Kim, {Tae Woo}",
year = "2012",
month = "11",
day = "1",
doi = "10.1172/JCI64057",
language = "English",
volume = "122",
pages = "4077--4093",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "11",

}

Noh, KH, Kim, BW, Song, KH, Cho, H, Lee, YH, Kim, JH, Chung, JY, Kim, JH, Hewitt, SM, Seong, SY, Mao, CP, Wu, TC & Kim, TW 2012, 'Nanog signaling in cancer promotes stem-like phenotype and immune evasion', Journal of Clinical Investigation, vol. 122, no. 11, pp. 4077-4093. https://doi.org/10.1172/JCI64057

Nanog signaling in cancer promotes stem-like phenotype and immune evasion. / Noh, Kyung Hee; Kim, Bo Wook; Song, Kwon Ho; Cho, Hanbyoul; Lee, Young Ho; Kim, Jin Hee; Chung, Joon Yong; Kim, Jae Hoon; Hewitt, Stephen M.; Seong, Seung Yong; Mao, Chih Ping; Wu, T. C.; Kim, Tae Woo.

In: Journal of Clinical Investigation, Vol. 122, No. 11, 01.11.2012, p. 4077-4093.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nanog signaling in cancer promotes stem-like phenotype and immune evasion

AU - Noh, Kyung Hee

AU - Kim, Bo Wook

AU - Song, Kwon Ho

AU - Cho, Hanbyoul

AU - Lee, Young Ho

AU - Kim, Jin Hee

AU - Chung, Joon Yong

AU - Kim, Jae Hoon

AU - Hewitt, Stephen M.

AU - Seong, Seung Yong

AU - Mao, Chih Ping

AU - Wu, T. C.

AU - Kim, Tae Woo

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Adaptation of tumor cells to the host is a major cause of cancer progression, failure of therapy, and ultimately death. Immune selection drives this adaptation in human cancer by enriching tumor cells with a cancer stem cell-like (CSC-like) phenotype that makes them resistant to CTL-mediated apoptosis; however, the mechanisms that mediate CSC maintenance and proliferation are largely unknown. Here, we report that CTL-mediated immune selection drives the evolution of tumor cells toward a CSC-like phenotype and that the CSC-like phenotype arises through the Akt signaling pathway via transcriptional induction of Tcl1a by Nanog. Furthermore, we found that hyperactivation of the Nanog/Tcl1a/Akt signaling axis was conserved across multiple types of human cancer. Inhibition of Nanog in a murine model of colon cancer rendered tumor cells susceptible to immune-mediated clearance and led to successful, long-term control of the disease. Our findings establish a firm link among immune selection, disease progression, and the development of a stem-like tumor phenotype in human cancer and implicate the Nanog/Tcl1a/Akt pathway as a central molecular target in this process.

AB - Adaptation of tumor cells to the host is a major cause of cancer progression, failure of therapy, and ultimately death. Immune selection drives this adaptation in human cancer by enriching tumor cells with a cancer stem cell-like (CSC-like) phenotype that makes them resistant to CTL-mediated apoptosis; however, the mechanisms that mediate CSC maintenance and proliferation are largely unknown. Here, we report that CTL-mediated immune selection drives the evolution of tumor cells toward a CSC-like phenotype and that the CSC-like phenotype arises through the Akt signaling pathway via transcriptional induction of Tcl1a by Nanog. Furthermore, we found that hyperactivation of the Nanog/Tcl1a/Akt signaling axis was conserved across multiple types of human cancer. Inhibition of Nanog in a murine model of colon cancer rendered tumor cells susceptible to immune-mediated clearance and led to successful, long-term control of the disease. Our findings establish a firm link among immune selection, disease progression, and the development of a stem-like tumor phenotype in human cancer and implicate the Nanog/Tcl1a/Akt pathway as a central molecular target in this process.

UR - http://www.scopus.com/inward/record.url?scp=84868618042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868618042&partnerID=8YFLogxK

U2 - 10.1172/JCI64057

DO - 10.1172/JCI64057

M3 - Article

C2 - 23093782

AN - SCOPUS:84868618042

VL - 122

SP - 4077

EP - 4093

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 11

ER -